CLINICAL TRIAL / NCT04978428
Epidiolex in Obsessive Compulsive Disorder and Related Disorders
- Interventional
- Recruiting
- NCT04978428
Contact Information
- Eve Chesivoir
An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study
The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.